Gilead Acquires Repare's Cancer Drug for $30 Million
Gilead Sciences purchases RP-3467, a promising cancer treatment targeting BRCA mutations, from Repare Therapeutics in a deal worth up to $30 million.
/ 2 items
Gilead Sciences purchases RP-3467, a promising cancer treatment targeting BRCA mutations, from Repare Therapeutics in a deal worth up to $30 million.
Repare Therapeutics (RPTX) announces acquisition by XenoTherapeutics for $1.82/share plus contingent value rights, expected to close Q1 2026.